Form 4: Director Stock Grant and Option Award at BioCryst

Steven K. Galson, a Director at BioCryst Pharmaceuticals, Inc., received a grant of Restricted Stock Units and stock options.

Summary

• Steven K. Galson, a Director of BioCryst Pharmaceuticals, Inc. (BCRX), was granted 15,294 Restricted Stock Units (RSUs) on June 11, 2026, with vesting occurring on the first anniversary of the grant date.
• Additionally, Galson received a grant of 33,540 stock options on June 11, 2026, with an exercise price of $8.50, exercisable from June 11, 2027, and expiring on June 11, 2036.
• The filing also notes that on July 23, 2025, Galson transferred 12,491 shares to a living trust, of which he is an indirect beneficial owner.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports routine equity grants to a director rather than significant financial or strategic developments.

Positives

• Director Galson received equity awards, indicating continued alignment with shareholder interests.
• The stock options have a strike price of $8.50, which may represent a discount to the current market price, offering potential upside for the director.
• The RSUs vest over one year, providing a short-term incentive.

Negatives

• The filing details a transfer of shares to a trust, which is a common estate planning or asset management strategy but does not represent new investment or a positive development for the company itself.

Risks

• The value of the granted RSUs and stock options is subject to the future performance of BioCryst Pharmaceuticals' stock price.
• If the stock price does not exceed the option exercise price of $8.50, the options may not be exercised profitably.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance. It solely reports on equity grants to a director.

Industry Context

StockSavvy.ai notes that grants of stock options and RSUs to directors are standard practice in the biopharmaceutical industry to attract and retain executive talent and align their interests with shareholders. The specific terms of these grants, including vesting schedules and exercise prices, are crucial for evaluating their potential impact.

Related Party Transactions

• Transfer of 12,491 shares by Steven K. Galson to a living trust on July 23, 2025, for which he is an indirect beneficial owner.

Stakeholder Impact

• Shareholders: The grants represent potential future dilution if options are exercised, but also signal director commitment and alignment with company performance.
• Employees: Indirect impact through director compensation structure, which is part of overall corporate governance.
• Management: Reinforces standard compensation practices for non-employee directors.

Next Steps

• Vesting of Restricted Stock Units on the first anniversary of the grant date (June 11, 2027).
• Potential exercise of stock options by Steven K. Galson starting from June 11, 2027, up to June 11, 2036.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, SEC Filing